Handa Pharmaceuticals, Inc.
TWO: 6620.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Fang-Yu Liu
- Headquarters
- Tainan City, Taiwan
- IPO year
- 2016
- Market cap
- NT$11.9B
- Website
- https://www.handapharma.com.tw
Loading 6620…
Loading profile data…Frequently asked questions about 6620
What does Handa Pharmaceuticals, Inc. (6620.TWO) do?
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company provides Quetiapine XR for the treatment of Schizophrenia; and Dexlansoprazole DR capsules. It also develops ONCORE, a proprietary drug delivery technology that was developed to imp...
Where does 6620.TWO trade?
Handa Pharmaceuticals, Inc. (6620.TWO) trades on the Taipei Exchange.
What sector is 6620.TWO in?
Handa Pharmaceuticals, Inc. (6620.TWO) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Handa Pharmaceuticals, Inc.?
Fang-Yu Liu is the chief executive officer of Handa Pharmaceuticals, Inc. (6620.TWO).
Where is Handa Pharmaceuticals, Inc. headquartered?
Handa Pharmaceuticals, Inc. is headquartered in Taiwan.
Does 6620.TWO pay a dividend?
Yes — Handa Pharmaceuticals, Inc. (6620.TWO) paid a trailing twelve-month dividend of TWD 1.51 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 6620.TWO go public?
Handa Pharmaceuticals, Inc. (6620.TWO) completed its initial public offering in 2016.